

The global generics market has grown at a rate of 20% in 2005; which is four times that of patented drugs and over three times that of pharmaceutical market. It is estimated to grow at a CAGR of 13.62% during the five-year period 2006-10. The market growth has been triggered by the rising number of patent expiries of blockbuster drugs and increasing healthcare expenditure. The US has the largest generics market and account to 44% of the global generics market. Teva Pharmaceuticals, based in Israel is the market leader in this industry followed by Sandoz.

SCOPE OF THE REPORT –

This report discusses in detail about the major generic markets while giving information on their market size, recent trends, major players, generics pricing and outlook for the market. The report also analyses the factors that drive the growth of the generics industry

- Overview of the generics industry in terms of size, geographical and therapeutic segmentation.
- Top 10 products in world's largest generics market
- Issues & Challenges
- Critical success factors
- Growth Drivers
- Mergers & Acquisitions
- Major Markets(North America, Europe and Asia Pacific)
- Emergence of India as an important player in global generics industry
- Amount & Area of R&D spend of major generic companies
- Regulations governing generics
- key patent expiries in the future
- outlook for the global generics industry for the next five years

COMPANIES COVERED IN THE REPORT –


In the report, 15 major generic companies have been profiled with information on their business and financial profile, key strategies, R&D pipeline and outlook for the company. The companies covered are –

Teva Pharmaceutical Industries, Sandoz, Merck KgaA, Ratiopharm, Watson Pharmaceuticals, Mylan Laboratories Inc, STADA Pharma, Pliva, Ranbaxy Laboratories, Barr Pharmaceuticals Inc, Andre Corporation, Hexal AG, Cipla, Actavis, Dr. Reddy's Laboratories Limited

FOR WHOM –

- Lifesciences companies (Bulk drugs, Formulations and Biopharma)
- Govt departments & agencies working in Pharma
- Consultants
- Associations & Consortia of the industry
- Research Institutions
- Education Institutes

To place your order, post your request to mktg@cygnusindia.com or fax at 91 – 40 – 23430201.



The report includes Executive summary, Highlights, Market Overview, Industry Trend, Major Markets, Growth drivers, Issues & Challenges, Research & Development, Regulations, Major players, Critical Success Factors, Key Patent Expiries (2006-09) and Outlook for Global Generic.

No of Pages : 127
List of Tables : 14
List of Figures : 32

Industry Insight

GLOBAL GENERICS

September 2006

Cygnus

Business Consulting & Research

Cygnus Business Consulting & Research

4th & 5th Floors, Astral Heights, Road No. 1, Banjara Hills, Hyderabad-500034, India

Tel: +91-40-23430203-05, Fax: +91-40-23430201, E-mail: info@cygnusindia.com

Website: www.cygnusindia.com

Disclaimer: All information contained in this report has been obtained from sources believed to be accurate by **Cygnus Business Consulting and Research** (Cygnus). While reasonable care has been taken in its preparation, Cygnus makes no representation or warranty, express or implied, as to the accuracy, timeliness or completeness of any such information. The information contained herein may be changed without notice. All information should be considered solely as statements of opinion and Cygnus will not be liable for any loss incurred by users from any use of the publication or contents

CONTENTS

1. EXECUTIVE SUMMARY	9
2. HIGHLIGHTS	12
3. MARKET OVERVIEW	14
3.1 Global generics market	14
3.2 Growth rate comparison	14
3.3 Geographical segmentation	15
3.4 Therapeutic segmentation	15
3.5 Ethical vs. OTC generics	16
3.6 Top 10 products in world’s largest generics market	16
3.7 Major generic companies	17
4. INDUSTRY TREND	18
4.1 Mergers and Acquisitions	18
4.2 Patent challenges	20
4.3 Regulatory changes	21
5. MAJOR MARKETS	22
5.1 North America	22
5.2 Europe	24
5.3 Asia Pacific	30
6. GROWTH DRIVERS	37
6.1 Cost advantage	37
6.2 Increasing patent expiries	37
6.3 Rising healthcare expenditure	38
6.4 Greater M&A activities	39
6.5 Shifting disease pattern	41
6.6 Changing age structure of the global population	42

7. ISSUES AND CHALLENGES	43
7.1 Authorized generics	43
7.2 Patent extension strategies	44
7.3 Price erosion leads to intense competition.....	45
7.4 Litigation and legal aspects	47
7.5 Competition from low cost manufacturers	48
8. RESEARCH AND DEVELOPMENT	49
8.1 R&D spend of major generic companies.....	49
8.2 Areas of R&D spend.....	49
9. REGULATIONS	52
9.1 Regulatory aspects in the US.....	52
9.2 Regulatory aspects in Europe	56
9.3 Regulatory aspects in Japan.....	57
9.4 International agreements on IPR protection	59
10. MAJOR PLAYERS	67
10.1 Teva Pharmaceutical Industries.....	67
10.2. Sandoz.....	70
10.3. Merck KGaA	73
10.4 Ratiopharm	75
10.5. Watson Pharmaceuticals.....	77
10.6. Mylan Laboratories Inc.....	79
10.7. STADA Pharmaceuticals.....	81
10.8. Pliva	84
10.9. Ranbaxy Laboratories.....	86
10.10. Barr Pharmaceuticals Inc.....	89
10.11. Andrx Corporation.....	91
10.12. Hexal AG	94
10.13. Cipla.....	95

10.14. Actavis	97
10.15. Dr. Reddy’s Laboratories Limited	99
11. CRITICAL SUCCESS FACTOR -----	103
11.1 Biogenerics	103
11.2 Outsourcing.....	104
11.3 Venturing into “difficult to make” generics	104
11.4 Mergers and Acquisitions	105
11.5 Investments in R&D	105
11.6 Identifying the right patents to challenge	106
11.7 Striking alliances	106
12. KEY PATENT EXPIRIES – 2006-09 -----	107
13. OUTLOOK -----	109
ANNEXURE I-----	111
ANNEXURE II-----	113

LIST OF FIGURES

- Figure 3.1: Global generics market - 2001-05 (USD bn)
- Figure 3.2: Pharmaceutical market vs Generics and Patented drugs growth rate - (2003-05)
- Figure 3.3: Geographical segmentation of global generics market – 2005
- Figure 3.4: Therapeutic segmentation of global generics market 2005
- Figure 3.5: Ethical vs. OTC generics – 2005
- Figure 3.6: Top 10 generic drugs in the US by value – 2005
- Figure 3.7: Top 10 generic players by revenue- 2005 (USD bn)
- Figure 4.1: M&A in global generics market - 2004-06 (USD bn)
- Figure 4.2: Number of Para IV filings in USFDA - 2004-06
- Figure 5.1: US generics market - 2001-05 (USD bn)
- Figure 5.2: Canada generics market - 2001-05 (USD bn)
- Figure 5.3: Germany generics market - 2001-05 (USD bn)
- Figure 5.4: UK generics market - 2001-05 (USD bn)
- Figure 5.5: France generics market - 2001-05 (USD bn)
- Figure 5.6: Italy generics market - 2001-05 (USD m)
- Figure 5.7: Spain generics market - 2001-05 (USD m)
- Figure 5.8: Japan generics market - 2001-05 (USD bn)
- Figure 5.9: China generics market - 2001-05 (USD bn)
- Figure 5.10: India generics market - 2001-05 (USD bn)
- Figure 5.11: Indian DMF submissions in the US - 2001-05
- Figure 5.12: Indian ANDA approvals - 2001-05
- Figure 6.1: Patent expiries by value - (2005-10) (USD bn)
- Figure 6.2: Healthcare expenditure as a % of GDP
- Figure 6.3: Global DALYs by disease - (2000-30)
- Figure 6.4: Percentage of population aged 55 & above as a percentage to the total population - (2000-2025)
- Figure 7.1: Generics pricing - The market scenario
- Figure 7.2: Generics competition and drug prices
- Figure 8.1: Top generic players by R&D spend- 2005 (USDm)
- Figure 8.2: Areas of R&D spend by generic firms

Figure 9.1: Generic drug approval procedure in the US

Figure 11.1: R&D spend as a percentage of sales of major generic players – 2005

Figure 13.1: Global generics market - 2006-10 (USD bn)

LIST OF TABLES

Table 4.1: Key M&A in global generics industry – 2004

Table 4.2: Key M&A in global generics industry – 2005

Table 4.3: Key M&A in global generics industry – 2006 (Jan-Jun'06)

Table 5.1: Top 5 generic companies in the US (MAT June 2006)

Table 5.2: Key M&A by Indian companies in the recent past

Table 5.3: Major players in India

Table 6.1: Cost comparison - Branded vs. Generic drugs

Table 7.1 List of authorized generics launched in the past

Table 7.2: Companies that used 6 months paediatric exclusivity in the past

Table 11.1: Key biopharmaceutical patent expiries – 2006

Table 12.1: Key Patent expiries 2006

Table 12.2: Key Patent expiries 2007

Table 12.3: Key Patent expiries 2008

Table 12.4: Key Patent expiries 2009